Literature DB >> 21733030

Two weeks of postsurgical therapy may be enough for high-risk cases of endocarditis caused by Streptococcus viridans or Streptococcus bovis.

P Muñoz1, M Giannella, F Scoti, M Predomingo, D Puga, A Pinto, J Roda, M Marin, E Bouza.   

Abstract

The duration of antimicrobial therapy after surgery for infective endocarditis (IE) is controversial. A short course of postsurgical therapy is currently accepted only for patients with negative valve culture. We performed a retrospective (1994-2008) analysis of patients who underwent surgery for IE in our hospital and had a high risk of complications ( one of more of the following: <2 weeks of antibiotic treatment before surgery; embolism; perivalvular extension; and positive valve culture) to compare outcomes of patients who received short-course antimicrobial therapy (SAT) (median 15 days) or long-course antimicrobial therapy (LAT) (median 32 days), irrespective of the results of valve culture. Our endpoints included length of hospital stay, renal and hepatic failure, relapse, re-infection, and mortality rates 1 year after surgery. During the study period, 140 patients underwent surgery for IE (valve replacement, 87.9%). Of these, 133 fulfilled the high-risk group criteria and 92 completed the antimicrobial schedule. Comparison of patients receiving SAT (37) and LAT (55) showed that the SAT group had a shorter length of hospital stay (29 vs. 40 days, p 0.01), and a trend towards lower frequency of renal failure (5.4% vs. 18.2%, p 0.11) and hepatic failure (5.4% vs. 9.1%, p 0.69), whereas mortality (5.4% vs. 3.6%, p 1), relapse (0% vs. 1.8%, p 1) and re-infection (5.4% vs. 3.6%, p 1) rates were similar between both groups. Multivariate analysis showed that IE caused by Streptococcus viridans or Streptococcus bovis was independently associated with SAT. Postsurgical SAT is safe, especially when IE is caused by Streptococcus viridans or Streptococcus bovis, even in patients at high risk of complications.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733030     DOI: 10.1111/j.1469-0691.2011.03594.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Infective Endocarditis Guidelines: The Challenges of Adherence-A Survey of Infectious Diseases Clinicians.

Authors:  Glen Huang; Siddhi Gupta; Kyle A Davis; Erin W Barnes; Susan E Beekmann; Philip M Polgreen; James E Peacock
Journal:  Open Forum Infect Dis       Date:  2020-08-24       Impact factor: 3.835

Review 2.  A narrative review of the interpretation of guidelines for the treatment of infective endocarditis.

Authors:  Umberto Benedetto; Sanjeet Singh Avtaar Singh; Cristiano Spadaccio; Marc R Moon; Francesco Nappi
Journal:  Ann Transl Med       Date:  2020-12

3.  Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial (SATIE).

Authors:  Carmen Olmos; Isidre Vilacosta; Javier López; Carmen Sáez; Manuel Anguita; Pablo Elpidio García-Granja; Cristina Sarriá; Jacobo Silva; Belén Álvarez-Álvarez; María Amparo Martínez-Monzonis; Juan Carlos Castillo; José Seijas; Amanda López-Picado; Vicente Peral; Luis Maroto; J Alberto San Román
Journal:  BMC Infect Dis       Date:  2020-06-16       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.